10 results about "Depression prevention" patented technology

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The present invention provides (S)- or (R)-ketamine prodrugs and compositions thereof for the treatment or prevention of depression and pain. [Solution] A compound of formula (1) or a pharmaceutically acceptable salt thereof (wherein R1 is hydrogen or alkyl, and R2 is a group of formula (6)) is provided. JPEG2026123016000361.jpg3980 JPEG2026123016000362.jpg2379

The invention discloses a homogeneous polysaccharide from Xiaoyao powder as well as a preparation method and application of the homogeneous polysaccharide. The homogeneous polysaccharide is composed of arabinose, galactose, mannose, glucose and fructose, and the weight-average molecular weight Mw of the homogeneous polysaccharide is 293.223 kDa. The polysaccharide is separated and purified from Xiaoyao powder through water extraction, alcohol precipitation, ion exchange column chromatography, gel column chromatography and other preparation methods. Experimental results show that the homogeneous polysaccharide can improve cortisol-induced zebra fish depression model behavioral performance and improve exercise activity, has anti-depression activity, and can be used for preparing drugs for treating or preventing depression.

This invention relates to pharmaceuticals, specifically to the use of Teadenol A in the preparation of medicaments for the treatment or prevention of depression. Experiments using an animal model of chronic unpredictable mild stress (CUMS) have demonstrated that Teadenol A can significantly improve depressive-like behaviors and reduce serum levels of pro-inflammatory factors (IL-1β, IL-6, TNF-α), suggesting that it has antidepressant effects.

Provided herein are compositions and methods for treating a disease or disorder using a therapeutically effective amount of an N-methyl-D-aspartate (NMDA) receptor modulator and a therapeutically effective amount of a target of rapamycin (mTOR) inhibitor.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The invention provides a medicine, the medicine comprises L-cystine and / or SLC7A11 molecules or a regulating reagent thereof, and the medicine can be used for treating and / or preventing depression related diseases. The invention further provides a biomarker comprising the L-cystine and / or the SLC7A11 molecule and application of the biomarker. The biomarker can be used as a target for screening and preparing products for detecting, preventing and / or treating depression. The L-cystine and / or the SLC7A11 molecule or the regulating reagent thereof has a good anti-depression effect, can promote the level of neuronal synaptic genes, and has an important application value in prevention and treatment of depression.

The invention discloses a pharmaceutical composition for treating and / or preventing depression, and belongs to the technical field of biological medicines. The technical problem to be solved is to significantly improve depression-like behaviors and protect nerve cells, and has an obvious effect on treatment and / or prevention of depression. According to the key point of the technical scheme, the pharmaceutical composition for treating and / or preventing depression comprises a secoiridoid glycoside compound, a xanthone glycoside compound and a beta-amyrin type pentacyclic triterpenoid compound in a mass ratio of 1: (0.25-6): (0.1-5), and one or more medically acceptable auxiliary materials.

The invention discloses a personalized depression risk screening and intervention system and method, and relates to the technical field of mental health screening. The invention aims to solve the problem of general formulation of depression research and intervention for people of different ages and different occupations. The system comprises a foreground application interface for man-machine interaction, a data acquisition module, a data analysis and prediction module and an intervention support module, the method comprises the following steps: customizing a personalized questionnaire according to the age, occupations and answering behaviors of a user based on a deep neural network and reinforcement learning; according to the method, intelligent layered assessment is designed for crowds of different ages and occupations, a dynamic anti-interference mechanism is adopted to filter distortion information, personalized psychological counseling schemes and medical suggestions are generated according to risk assessment levels, intervention strategies are continuously optimized, a closed-loop service system is formed, early screening and personalized intervention of depression are achieved, and the risk assessment level is improved. Intelligent and precise construction of mental health and depression prevention ecology is promoted.